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Retinoblastoma protein (Rb) is a key regulator of cellular proliferation, controlling entry into G1/S in the cell
cycle, largely through its action in binding the cellular transcription factor E2F, which activates genes
important in DNA synthesis. Small DNA tumor viruses encode gene products which can functionally inactivate
Rb, promoting cellular proliferation and viral DNA synthesis. In this study, the Epstein-Barr virus (EBV)
immediate-early lytic gene product, BRLF1 (R), is shown to bind Rb in vivo, shortly after induction of the viral
lytic cycle in EBV-infected Akata cells. Furthermore, the temporal kinetics of R-Rb interaction correlate with
displacement of E2F1 from Rb. Mapping of the domains required for the interaction of R and Rb proteins
reveals that R binds specifically to the N terminus of Rb, outside the Rb pocket, and that the first 200 amino
acids of R are required for this interaction. The interaction of R and Rb may initiate cell cycle progression and
facilitate viral DNA synthesis during lytic replication.
Epstein-Barr virus (EBV), a lymphotrophic human gamma-
herpesvirus, is the causative agent of infectious mononucleosis
and is associated with several lymphoid malignancies, including
Burkitt’s lymphoma (BL), Hodgkin’s disease, and lymphopro-
liferative diseases in immunocompromised persons (reviewed
in reference 38). EBV also appears to be the primary agent in
the epithelial cancer nasopharyngeal carcinoma (54).
Infection of primary B cells is predominantly latent, with
only a subset of viral genes being expressed. Following infec-
tion, cells rapidly enter a proliferative phase and eventually
become immortalized. Six latency-associated genes are re-
quired for the immortalization process, the Epstein-Barr nu-
clear antigens (EBNA1, -2, -3A, -3C, and -LP) and latent
membrane protein 1. The viral genome in latently infected
cells is maintained as a circular episome which is replicated by
the host polymerase (41).
The mechanism of cell immortalization driven by EBV is not
fully understood but appears to differ from that of the small
DNA tumor viruses. Adenovirus (55, 78, 80), papillomavirus
(19, 45, 77), and simian virus 40 (17, 45, 55) all encode viral
oncoproteins which functionally inactivate the tumor suppres-
sor gene products, p53 and Rb (43, 46, 74). Inactivation of Rb
indirectly stimulates cellular proliferation (79), while coordi-
nate inactivation of p53 prevents induction of the apoptotic
pathway (59). Coordinate inactivation of tumor suppressor
genes by small DNA tumor viruses is thought to promote the
induction of S phase in cells, which is necessary for viral DNA
replication. The induction of proliferative signals and suppres-
sion of apoptotic signals can lead to unrestricted cellular pro-
liferation and, in some cases, cell transformation. In contrast,
transformation by EBV is characterized by latent infection;
lytic viral DNA replication is not thought to occur in cells
destined for immortalization, and no virus is produced in the
immortalized cells.
The EBV latent gene product, EBNA3C (also called EBNA6),
has been reported to bind Rb in vitro and enhance transfor-
mation of rat embryo fibroblasts by ras. EBNA3C also trans-
activated the B-myb promoter in an E2F-dependent manner,
which suggests that EBNA3C can inactivate Rb, releasing free
E2F (49). A second EBV gene product, EBNALP (EBNA5), is
reported to bind p53 and Rb in vitro and to colocalize with Rb
in the cell (64, 65). The functional significance of this interac-
tion is unknown (35, 64). Both EBNA3C and EBNALP lack
the LXCXE motif found in other viral proteins which bind the
Rb pocket. It is possible that either of these latency genes can
contribute to cellular transformation if it is able to bind Rb in
vivo; however, viral DNA synthesis, which occurs in produc-
tively infected cells, would not be affected.
In contrast to latent infection in B cells, EBV infection of
epithelial cells is usually productive and results in cell lysis.
Immunosuppression, however, may trigger reactivation of the
virus in latently infected B cells, which leads to productive
infection (48). This switch to a replicative pattern of viral gene
expression can be mimicked by treating latently infected cells
with phorbol ester (16, 84) or immunoglobulin G (IgG) anti-
body (66). Upon reactivation, the two key EBV immediate-
early (IE) lytic genes, BZLF1 and BRLF1, are expressed (5,
68). These genes encode transactivators which activate viral
and cellular promoters and lead to an ordered cascade of viral
gene expression (6, 20–22, 29, 31, 37, 57). Expression of the
BZLF1 gene product, Z (also called Zta or EB1), alone is
sufficient to activate the EBV lytic cascade (12–14, 25, 69).
Recent studies implicate Z in regulation of cellular prolifera-
tion. Z can bind p53 and inactivate p53-mediated transactiva-
tion functions in transient assays (83), and expression of Z in
some epithelial tumor cell lines causes G0/G1 arrest in a p53-
dependent manner. Expression of Z in these cells also results
in upregulation of the cyclin-dependent kinase inhibitors p21
and p27, which causes accumulation of the hypophosphory-
lated form of Rb (8).
Like Z, the BRLF1 gene product, R (Rta), is a transactivator
and can act alone or in tandem with Z to activate viral and
cellular promoters (11, 12, 15, 24, 28, 31, 37, 44, 53). Recently,
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it has been shown that BRLF1 alone can initiate activation of
lytic gene expression in latently infected epithelial cell lines
(81). The 605-amino-acid (aa) R protein contains two transac-
tivation domains and an N-terminal DNA-binding and dimer-
ization domain (29, 44). R can activate promoters both by
binding a specific DNA sequence, an R-responsive element
(29, 44), and indirectly, possibly by activating or recruiting
cellular transcription factors (42, 81, 82). Promoters activated
in the latter manner include BRLF1 itself (57, 82), the human
immunodeficiency virus long terminal repeat (52), and c-myc
(26). Recent data show that the promoter for the EBV DNA
polymerase, which is responsible for lytic viral DNA replica-
tion, is also activated by R indirectly through the transcription
factors USF and E2F (42).
The Rb protein suppresses cellular proliferation by associ-
ating with and suppressing the activity of cellular transcription
factors, in particular the E2F family of proteins, which activate
genes important in cellular DNA replication (2, 47). Active,
hypophosphorylated Rb can sequester E2F, preventing entry
of cells into S phase. Phosphorylation of Rb by cyclin-depen-
dent kinase complexes inactivates Rb and releases E2F, which
subsequently activates promoters for genes involved in DNA
synthesis (1, 40). Viral oncoproteins encoded by the small
DNA tumor viruses can bind to underphosphorylated Rb and
displace E2F, driving cellular proliferation (reviewed in refer-
ence 75).
We hypothesized that since R can indirectly activate some
promoters by recruitment or activation of other transcription
factors, including E2F, R might interact with the Rb protein
and displace associated transcription factors. In this study, we
show that R specifically binds Rb protein at early times fol-
lowing viral reactivation. The interaction is limited to early
times following induction and correlates temporally with re-
lease of E2F1 from Rb.
MATERIALS AND METHODS
Plasmids. Plasmid pGEX2T, containing the glutathione S-transferase (GST)
open reading frame, was purchased from Pharmacia. GSTEBNA2 was prepared
by PCR amplification of the EBNA2 open reading frame from DNA prepared
from EBV-infected B95-8 cells, using the amplimers 59 AACGCTGAGATCTA
TGCCTACATTCTATCTTGCG 39 and 59 AATCAAAGATCTTGATTACTG
GATGGAGGGGCGAG 39. The PCR product was cloned into the BamHI site
of pGEX2T. Plasmid GSTE2F was a gift from Joe Nevins. GST59Rb (previously
called HURB; aa 1 to 380) and the GST mutant plasmids D39-89, D89-140,
D126-166, D249-309, D309-343, and D343-383 were generous gifts from Jonathan
Horowitz and have been described previously (60, 61). GST39Rb (aa 377 to 928)
has been described elsewhere (27). Plasmid pGEXR (53) and the R mutant
plasmids used for in vitro translation, Rt201, Rt356, Rt356i81, Rt515, RD2-22,
and RD81-184 (44), were generous gifts from Evelyne Manet and Alain Sergeant
and have been previously described. Plasmid RcDNA, used for in vitro transla-
tion, was a gift from Shannon Kenney. pRBd59 was a gift from R. Weinberg;
pBSKglobE2F, a gift from Ed Harlow, contains E2F1 cDNA (nucleotides 130
to 1456) in pBSKglob.
Cell culture. DG75 is an EBV-negative BL cell line (4); Akata is an EBV-
infected type 1 lymphoblastoid line (66, 67). Akata and DG75 cells were main-
tained in RPMI 1640 with 10% fetal bovine serum (GIBCO-BRL, Gaithersburg,
Md.) and antibiotics at 37°C in 5% CO2. To induce the latently infected Akata
cell line, cells were treated with 0.1 mg of anti-human IgG (Sigma, St. Louis,
Mo.) per ml. Samples were harvested at various times following induction.
In vitro translation. Plasmids were transcribed and translated in vitro in the
presence of [35S]methionine, using the TnT system (Promega, Madison, Wis.)
according to the manufacturer’s specifications and with the appropriate RNA
polymerase (SP6 or T7; Promega).
Bacterial expression of GST fusion proteins. GST plasmids were transformed
into Escherichia coli BL21, and expression was induced by 0.1 mM isopropyl-1-
thio-b-D-galactopyranoside (IPTG). The samples were incubated at 37°C for 2 h
with shaking, then harvested, and centrifuged for 30 min at 5,000 rpm. The
bacterial pellet was resuspended in phosphate-buffered saline solution (PBS) to
1/10 the original culture volume. For binding to beads, the bacteria were lysed by
freezing and thawing, followed by sonication on ice. After centrifugation, 20 to
800 ml of supernatant fluid was incubated with 25 ml of glutathione-Sepharose
beads (Pharmacia, Uppsala, Sweden) in a total volume of 1 ml in PBS for 30 min
at 25°C. The beads were washed in buffer (20 mM HEPES, 150 mM KCl, 1%
Nonidet P-40, 1 mM dithiothreitol), then boiled in Laemmli buffer, and sep-
arated by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-
PAGE). The amount of GST fusion protein was determined by Coomassie blue
staining of the gel.
GST protein precipitation. Fusion protein was loaded onto beads as described
above and then incubated with 35S-labeled reticulocyte lysate in 500 ml of buffer
(above) for 90 min at 4°C. The beads were washed with buffer, then resuspended
in Laemmli buffer, and boiled. The samples were resolved by SDS-PAGE. The
gel was fixed in 25% methanol–7% acetic acid for 30 min, then incubated in 1 M
sodium salicylate for an additional 30 min, and subjected to autoradiography.
Immunoprecipitation. Cells were harvested, washed in PBS, resuspended in
ELB1 buffer (0.25 M NaCl, 0.1% Nonidet P-40, 0.05 M HEPES [pH 7.0], 0.001
M phenylmethylsulfonyl fluoride, 0.005 M EDTA, 0.5 mM dithiothreitol), and
lysed by repeated freezing and thawing. Total protein content was determined
with a Bio-Rad (Richmond, Calif.) protein assay kit. For immunoprecipitations,
200 to 800 mg of cellular lysate was incubated with antibody in a volume of 1 ml
(ELB1 buffer) on ice for 1 h. The samples were incubated for an additional 3 h
at 4°C with shaking. Protein A-Sepharose (50 ml) (Pharmacia) was added, and
the incubation continued for an additional 60 min. The beads were pelleted and
washed four times with ELB1 buffer, then resuspended in Laemmli buffer, and
boiled.
Immunoblot analysis. Samples in Laemmli buffer were resolved by SDS-
PAGE (6 to 12% polyacrylamide) and then transferred to an Immobilon mem-
brane (Millipore, Bedford, Mass.). The membrane was blocked with 5% dry milk
powder in TBST (0.9% NaCl, 0.02 M Tris-HCl [pH 7.5], 0.05% Tween 20). The
membrane was incubated in primary antibody in blocking solution for 60 min,
washed three times with TBST, and then incubated in secondary antibody (horse-
radish peroxidase-conjugated anti-mouse or anti-rabbit Ig; Amersham, Bucking-
hamshire, England) for 60 min. The membrane was washed three times with
TBST and then developed in enhanced chemiluminescence reagents according
to the protocol of the manufacturer (Amersham).
Antibodies. The Rb-specific antibody, C-15X, and the E2F1 antibodies, KH95
and sc193, were from Santa Cruz Biotechnology (Santa Cruz, Calif.). The Rb
antibody used for immunoprecipitation, AB-1, was from Oncogene Science
(Cambridge, Mass.). The R monoclonal antibody, 8C12, was a generous gift from
Alain Sergeant. The R2 antibody is an affinity-purified polyclonal serum raised
against the R peptide corresponding to R aa 1 to 20 (CMRPKKDGLEDFLRLT
PEIKK). The peptide was synthesized in the protein chemistry facility at the
University of North Carolina, Chapel Hill. Immunization of rabbits and antibody
purification were performed by Immunodynamics (La Jolla, Calif.).
Phosphatase assay. Twenty micrograms of protein was incubated in buffer
with 2,000 U of lambda phosphatase for 3 h at 30°C in a total volume of 50 ml
according to the protocol of the manufacturer (New England Biolabs). Control
samples containing no phosphatase were incubated under the same conditions.
The samples were separated by SDS-PAGE as described above.
RESULTS
R binds Rb in vitro. Since the EBV IE protein Z can bind
and functionally inactivate p53 (81), we investigated whether
the second EBV IE protein, R, could interact with the Rb pro-
tein. Radiolabeled R, Rb, and E2F proteins were expressed in
reticulocyte lysates and then incubated with equivalent amounts
of bacterially expressed GST fusion proteins, as judged by Coo-
massie staining. As expected, the positive control, GSTE2F
(Fig. 1A, lane 5), specifically precipitated radiolabeled Rb,
as did the viral fusion protein, GSTR (lane 7). Rb did not in-
teract with beads alone, GST-loaded beads (lanes 3 and 4),
or GSTEBNA2, an EBV latency protein used as a negative
control (lane 6). Surprisingly, GSTE2F could simultaneously
precipitate cotranslated R and Rb proteins (lane 8). This was
unexpected, as most proteins such as E2F that interact with Rb
specifically bind its pocket region, and the presence of another
Rb-binding protein, such as a viral oncoprotein, usually results
in displacement of E2F (75). These results indicated that R
may bind Rb outside the E2F-binding pocket region or that R
may interact with E2F directly.
To address this question and to test whether the reciprocal
interaction of R and Rb could be demonstrated, GST59Rb (aa
1 to 380) and GST39Rb (aa 377 to 928) were tested for inter-
action with radiolabeled R or E2F protein. Radiolabeled R
protein was able to form dimers with GSTR (Fig. 1B, lane 11)
and was precipitated by 59Rb, but not 39Rb, which contains the
pocket region (lanes 5 and 6). R did not interact with beads or
GST alone (lanes 3 and 4) and did not directly bind E2F (lane
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12). As R and E2F bind different regions of Rb, this result is in
agreement with the observation that Rb can interact simulta-
neously with R and E2F. More importantly, lanes 9 and 10
show that the GST-Rb constructs performed as expected: E2F
was precipitated only by 39Rb, which contains the pocket do-
main, and not by 59Rb (lanes 9 and 10). An R doublet precip-
itated by Rb (lane 5) may be due to posttranslational modifi-
cation of R or to a truncated form resulting from internal
initiation or to partial protein degradation.
To confirm that R could not interact directly with E2F,
GSTR was incubated with radiolabeled E2F protein. E2F pro-
tein was precipitated by the positive control, GST39Rb (Fig.
1C, lane 5), but not by GSTR (lane 6). E2F was not precipi-
tated by beads alone, GST, or GST59Rb (lanes 2 to 4). GSTR
precipitated Rb protein alone from a mixture of radiolabeled
E2F and Rb (lane 7), indicating that the GSTR protein was
indeed functional. An additional band which binds to GSTR is
believed to be a degradation product of Rb, as it migrates more
rapidly than E2F. The results in Fig. 1C, lane 7, differed from
those in Fig. 1A, lane 8, where a tripartite complex of R, Rb,
and E2F was observed. These differences may be due to the
fact that the reticulocyte lysates were cotranslated in the ear-
lier experiment (Fig. 1A) but not in Fig. 1C.
Taken together, these data indicate that R can bind Rb in
vitro and that binding of R occurs outside the Rb pocket. The
interaction is probably not mediated by E2F, as R did not
interact directly with E2F, but there is potential for the for-
mation of a complex containing R, Rb, and E2F proteins.
The EBV R protein coprecipitates Rb from induced Akata
cells. To determine whether the proteins interacted in vivo,
coimmunoprecipitations were performed with BL cells. Akata
is a latently EBV-infected BL line which expresses IgG; viral
replication can be reactivated by cross-linking of the surface Ig
with antibody. Induction of viral lytic cycle genes is rapid and
synchronous and occurs in 50 to 75% of the cells (66, 68).
Samples were collected from Akata cells following IgG in-
duction, and protein lysates were prepared. Protein (600 mg)
was immunoprecipitated with R2 antibody, which recognizes R
protein; the complexes were separated by SDS-PAGE and
then immunoblotted with antibody C-15X, a polyclonal serum
which recognizes all forms of the Rb protein (Santa Cruz). R
specifically coprecipitated Rb at 6 and 12 h postinduction (Fig.
2A, lanes 5 and 6). R2 antibody did not precipitate Rb protein
from uninduced cells, which do not express R (lane 4), nor did
R2 precipitate Rb from radiolabeled reticulocyte lysates (lane
2). The interaction of R and Rb was limited to early times
postinduction; it was not detected by 24 h postinduction (Fig.
2A, lanes 7 to 9).
Western blot analyses of lysates from the same time course
were performed to detect R and Rb protein directly. As ex-
pected, R protein was not detected in uninduced Akata cells
but was readily detectable 6 h postinduction (Fig. 2B). Rb
protein levels remained constant in both induced and unin-
duced Akata cells (Fig. 2C). Clearly, the interaction of R and
Rb at early times is specific, and the lack of complex formation
at later times is not limited by availability of the two proteins.
It is possible that posttranslational modification of the pro-
tein(s) or availability of a tethering protein contributes to reg-
ulating R-Rb interaction.
Rb-E2F1 complex is disrupted by induction of the lytic cycle
in EBV-infected Akata cells. To determine whether E2F1,
which binds hypophosphorylated Rb, was associated with Rb in
FIG. 1. EBV R protein binds Rb in vitro. Bacterially expressed GST fusion proteins linked to glutathione-Sepharose beads (Pharmacia) were incubated with
35S-labeled reticulocyte lysate programmed with Rb, R, or E2F DNA for 1 h at 4°C. (A) 35S-labeled Rb (lane 2) was incubated with beads alone (lane 3), GST-loaded
beads (lane 4), or GSTEBNA2 as a negative controls (lane 6). GSTE2F (lane 5) and GSTR (lane 7) bound in vitro-labeled Rb. GSTE2F was incubated with cotranslated
R and Rb protein (lane 8). (B) Radiolabeled R or E2F protein was incubated with GST proteins linked to Glutathione beads. Lanes 3 and 7, beads alone; lanes 4 and
8, GST; lanes 5 and 9, GST59Rb (aa 1 to 380); lanes 6 and 10, GST39Rb (aa 377 to 928); lane 11, GSTR; lane 12, GSTE2F. Direct loading of in vitro-labeled R and
E2F proteins is shown in lanes 1 and 2, respectively. (C) GST fusion proteins were incubated with 35S-labeled E2F-1 protein. Lane 1, directly loaded E2F protein; lanes
2 to 4, E2F incubated with beads alone, GST-loaded beads, and GST59Rb, respectively. GST39Rb precipitated E2F (lane 4), but GSTR did not (lane 5). GSTR
incubated with equal amounts of Rb and E2F proteins is shown in lane 7.
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Akata cells following induction, Akata protein lysates (the
same samples as used in Fig. 2) were immunoprecipitated with
Rb-specific antibody AB-1, and the complexes were probed for
E2F1 protein. E2F1 was bound to Rb in uninduced Akata cells
(Fig. 3A, lane 2) but was released from Rb at 6 and 12 h
postinduction (lanes 3 and 4). The complexes reassociated by
24 h (lane 5). Therefore, the kinetics of E2F release from Rb
paralleled those of R and Rb association. Rb-E2F complex
dissociates again at 48 h (lane 7) independent of R binding,
and this may reflect cell cycle-associated events such as Rb
phosphorylation.
The in vitro data suggested that a complex of R, Rb, and
E2F proteins might form in some circumstances. To determine
whether R might directly bind E2F in vivo, or if R-Rb associ-
ation might include E2F, Akata protein from induced cells was
immunoprecipitated with the R-specific antibody R2, and the
complexes were probed with antibody to E2F1. Figure 3B, lane
1, shows E2F1 protein directly in uninduced Akata cell lysate.
E2F protein was not coprecipitated with R in any of the in-
duced Akata lysate samples (lanes 2 to 7). These data demon-
strate that R does not bind E2F1 directly and confirm that
R-Rb association is not dependent on E2F.
Next, total E2F protein in Akata lysates was determined by
Western blot analysis. Akata cells were harvested at 0, 3, 6, 12,
and 24 h following IgG cross-linking, and whole-cell lysates
were prepared. Immunoblot analysis was performed with anti-
body sc193 (1:100) (Fig. 3C). E2F levels appear to increase
at early times following induction of the lytic cycle (Fig. 3C).
Therefore, the disappearance of the E2F-Rb complex at 6 and
12 h postinduction, seen in Fig. 3A, is not due to a decrease in
E2F protein levels.
Phosphorylation of R and Rb following induction of the lytic
cycle. Since Rb is a phosphoprotein and R may be phosphor-
ylated, we investigated the phosphorylation status of R and Rb
following induction of the lytic cycle in Akata cells. Akata cells
were induced by IgG cross-linking as described above, samples
were harvested following post induction at the times indicated,
and protein lysates were prepared. To distinguish differently
migrating forms of the proteins, we separated protein lysate
samples by SDS-PAGE at conditions selected to enhance sep-
aration of the desired protein and then performed immunoblot
analysis. For detection of Rb, 25 mg of lysate was separated on
a 7% polyacrylamide gel. The protein was transferred to an
Immobilon membrane and probed with antibody C-15X. R was
detected with antibody 8C12 (1:100) following separation of
200 mg of protein with a 10% polyacrylamide gel. Multiple
forms of both proteins were detected. At least two forms of Rb
were detected in uninduced Akata cells (Fig. 4A, lane 1). At
3 h postinduction, virtually all Rb protein was underphosphor-
ylated (lane 2). A more slowly migrating species of Rb started
to accumulate at 6 h postinduction (lane 3) and became the
predominant form of Rb at later times (lanes 4 to 8). Presum-
ably Rb-binding proteins would preferentially interact with Rb
at early times after induction.
A rapidly migrating form of R was detected at 3 and 6 h
postinduction (Fig. 4B, lanes 2 and 3). A second, more slowly
migrating species was seen at later times following induction
(lanes 4 to 8). To confirm that the differentially migrating
FIG. 2. EBV R protein precipitates Rb in induced Akata cells. EBV-infected
Akata cells were treated with 0.1 mg of anti-IgG (Sigma) per ml, and samples
were harvested at various times postinduction (hours p.i.). (A) Akata protein
lysate samples were immunoprecipitated with R2 antiserum (1:100) and then
probed for Rb with antibody C-15X (1:5,000; Santa Cruz). Shown are Western
blots of in vitro-translated Rb protein (lane 1) and uninduced Akata protein
(lane 3) and immunoprecipitation (IP) of in vitro-translated Rb (lane 2) and
Akata samples induced for 0, 6, 12, 24, 36, or 48 h (lanes 4 to 9). (B and C)
Western blots of induced and uninduced Akata protein samples probed with
antibody 8C12 (1:10) (B) or Rb-specific antibody C-15X (C).
FIG. 3. Association of Rb and E2F in EBV-infected Akata cells. Akata cell
protein samples were collected at various times after anti-IgG induction (hours
p. i.). (A) A 200-mg aliquot of lysate was immunoprecipitated (IP) with antibody
to Rb protein (AB-1; Oncogene Science). The complexes were resolved by
SDS-PAGE and probed for E2F1 protein (KH95; Santa Cruz). Lane 1, total
E2F1 protein in 50 mg of Akata lysate; lanes 2 to 7, immunoprecipitations with
Rb-specific antibody. (B) Akata protein samples were immunoprecipitated with
R2 antibody and then immunoblotted with antibody for E2F1 protein (lanes 2 to
7). Direct loading of uninduced Akata lysate probed for E2F1 protein is shown
in lane 1. (C) Akata lysate samples (100 mg) were immunoblotted with E2F1
antibody sc193 (1:100; Santa Cruz).
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forms of R and Rb were due to phosphorylation, we performed
a phosphatase assay. Twenty micrograms of total lysate was in-
cubated with 2,000 U of lambda phosphatase as described, fol-
lowed by electrophoresis and immunoblot analysis. When sam-
ples were incubated in the presence of phosphatase, both R and
Rb proteins were reduced to a single rapidly migrating species
(Fig. 4C), indicating that the more slowly migrating species of
the proteins were phosphorylated derivatives of each protein.
R aa 1 to 201 are required for Rb interaction. Next we de-
termined which region of the R protein specifically interacted
with Rb. For mapping studies, a series of mutant R constructs
which contain C-terminal or internal deletions (44) were trans-
lated and radiolabeled with [35S]methionine in reticulocyte
lysates, using T7 RNA polymerase (R and RD2-22) or SP6
RNA polymerase (Rt201, Rt356, Rt356i81, Rt515, and RD81-
184) (Fig. 5A). The proteins were analyzed by gel electro-
phoresis followed by autoradiography to confirm that each of
the translated proteins was of the expected molecular weight
(data not shown). Equivalent amounts of the radiolabeled pro-
teins as judged by autoradiography were precipitated with
GST59Rb fusion protein. Figure 5B shows that all of the C-
terminally truncated R mutants interacted in vitro with 59Rb
(lanes 5 to 8), but the internal deletion mutant, RD2-22 (lane
4), did not bind 59Rb. Another internal deletion mutant, RD81-
184, also failed to coprecipitate with Rb (data not shown).
These R mutants were previously used to map functional
domains in the R protein. Manet et al. (44) localized the di-
merization domain of R to aa 1 to 232, within the DNA-
binding domain (aa 1 to 280). It was also shown that mutant
Rt201, as well as the two deletion mutants, RtD2-22 and
RtD81-184, were all deficient in both dimerization and DNA-
binding capacity (44). Therefore, dimerization of R is not nec-
essary for the interaction with Rb, as mutants Rt201 and
Rt356i81 can precipitate the Rb protein.
Mapping the regions of the Rb protein that interact with R.
Results from Fig. 1 show that R specifically binds to the 59 end
of Rb, outside the Rb-binding pocket, perhaps because R does
not contain an LXCXE motif previously found in the other
proteins that bind the Rb pocket (46). However, possible func-
tions for the N-terminal region of Rb have recently been un-
covered (reviewed in reference 76). Therefore, the region of
Rb necessary for interaction with R was mapped more closely.
A series of GST59Rb constructs which contained internal de-
letions (a generous gift from J. Horowitz) are shown in Fig. 6A
(61). Equivalent amounts of bacterially expressed mutant pro-
teins, as judged by Coomassie blue staining (data not shown),
were incubated with radiolabeled, in vitro-translated R pro-
tein. As shown in Fig. 6B, deletion of two separate regions in
Rb interfered with binding of R. Deletion of aa 39 to 89 (lane
4) completely disrupted interaction with R, and deletion of aa
249 to 309 significantly reduced the amount of R binding (lane
7). When the same experiment was repeated with radiolabeled
Rt201 instead of full-length R, the results were similar (data
not shown). These data indicate that aa 39 to 89 in Rb are
critical for interaction with R. Another deletion, from aa 249 to
309, decreased R binding, perhaps because of conformational
changes caused by the deletion.
DISCUSSION
The Rb and p53 gene products were identified by their func-
tion as tumor suppressor proteins, but their effects are more
encompassing; it is now known that these proteins are critical
FIG. 4. Phosphorylation of R and Rb following lytic induction in Akata cells.
Total protein lysate samples from induced Akata cells at various times postin-
duction (hours p.i.) were separated by SDS-PAGE and then probed for Rb (A)
or R (B) protein. (C) A 20-mg aliquot of each lysate was incubated with lambda
phosphatase (New England Biolabs) for the times indicated at 30°C prior to
immunoblot analysis.
FIG. 5. Structures and functions of R mutants. (A) Structures of R mutants
used in mapping studies (generous gifts from Evelyne Manet). DNA binding and
dimerization were described previously (44). (B) R plasmids were transcribed
and translated in vitro in the presence of [35S]methionine, using the TnT system
(Promega). Radiolabeled R protein was incubated with glutathione beads (lane
2), GST-beads (lane 3), or GST59Rb (aa 1 to 380; lanes 4 to 8) for 90 min at 4°C.
The samples were washed and separated by electrophoresis as described in the
text.
VOL. 72, 1998 EBV R PROTEIN BINDS Rb 8047
for normal cellular proliferation. It is not surprising, then, that
these proteins may be targeted not only during cellular trans-
formation but also during viral infection to circumvent normal
controls on cellular proliferation and establish an environment
that favors viral DNA replication. This may be a common
theme not only among the small DNA tumor viruses but also
among other DNA viruses. Human cytomegalovirus encodes a
gene product, IE2, which binds Rb and inactivates its E2F-
mediated growth-suppressive function (27, 58), and infection
of cells with this virus leads to a rapid burst in DNA, RNA, and
protein synthesis (23, 62, 63, 70). Infection of cells with herpes
simplex virus type 1 leads to an increase in S-phase E2F com-
plexes and free E2F (30).
Previous data from our laboratory suggested that Rb may be
a target for the R protein. R activation of the promoter for the
EBV pol gene has been mapped to elements which bind the
transcription factors USF and E2F; mutation at either site
reduced R-mediated activation of pol (42). Additional promot-
ers are activated by R in an indirect manner (26, 52, 57, 82).
Taken together, these results indicate that R may activate
some promoters by activation of cellular transcription factors.
One mechanism by which indirect activation of promoters
could occur is through interaction of R and Rb proteins and
release of transcription factors bound to Rb.
The IE gene product, R, specifically binds Rb both in vitro
and in vivo. The interaction of R and Rb occurs shortly after
induction of the viral lytic cycle in Akata cells treated with IgG
antibody and is limited to early times following induction.
Beyond 24 h postinduction no interaction could be detected
even though levels of R and Rb remained constant for 48 h,
which indicates that the interaction may be regulated post-
translationally, possibly by phosphorylation. Rb activity is reg-
ulated by phosphorylation (71), and R may also be a target for
phosphorylation by cellular kinases (51). We show here that R
is indeed a phosphoprotein and that the status of both R and
Rb phosphorylation varies following induction of the lytic cy-
cle. Multiple forms of Rb are detected in uninduced cells, but
hypophosphorylated forms of Rb accumulate 3 h postinduc-
tion, and Rb becomes progressively more phosphorylated at
later times after induction (Fig. 4A and C). Therefore, it ap-
pears that induction may trigger a rapid, transient dephosphor-
ylation of Rb. The mechanism underlying Rb dephosphoryla-
tion and the subsequent phosphorylation seen at later times
remain to be investigated. Similarly, R appears to be under-
phosphorylated or not phosphorylated when it is first detected
after induction; at later times, a mixture of phosphorylated and
unphosphorylated forms is detected (Fig. 4B and C). There-
fore, the strongest interaction of R and Rb proteins occurs at
early times following induction, when both proteins are pre-
dominantly underphosphorylated or not phosphorylated. The
disruption of R and Rb complexes could be due to increas-
ing phosphorylation of R or Rb or both. It has not yet been
determined precisely which phosphorylated form of Rb can
bind R, but it is likely that R binds underphosphorylated Rb, as
all proteins to date which bind Rb preferentially bind the
underphosphorylated form of the protein (76). These data are
exciting, as they indicate that EBV specifically targets Rb early
in the lytic cycle.
E2F1 is bound to Rb in latently infected Akata cells. This
finding suggests that at least some of the Rb protein is hypo-
phosphorylated in these cells. This result contrasts with data
obtained for lymphoblastoid cell lines, where Rb is known to
be hyperphosphorylated. The result probably reflects differ-
ences between type 1 (Akata) and type 3 (lymphoblastoid cell
lines) latent viral gene expression (3, 7).
The release of E2F from Rb during viral reactivation corre-
lates temporally with the kinetics of R-Rb interaction. It would
be tempting to speculate that R binding to Rb results in the
displacement of E2F, which could then activate both viral and
cellular E2F-responsive promoters, linking R to proliferation
and/or cell cycle progression. However, the data suggest that
interaction of R and Rb may have additional functional con-
sequences.
The in vitro data indicate that R, Rb, and E2F may form a
tripartite complex under some circumstances (Fig. 1A and C),
whereas in vivo, E2F displacement from Rb clearly correlates
with R binding to Rb. A complex of all three proteins formed
only when R and Rb were cotranslated before addition of E2F
(Fig. 1A). Therefore, it is likely that the conformation of Rb
protein is changed with each binding partner, and this change
may determine whether additional proteins can then bind Rb.
The cellular context, i.e., other proteins binding to Rb, could
determine whether binding of R might displace E2F. Other
factors may play a role in regulating Rb protein interactions;
since R is a phosphoprotein, it is possible that the phosphor-
ylation status of R determines whether E2F is released. R has
not been shown to have any kinase activity and thus is unlikely
to play a direct role in Rb phosphorylation, but it is possible
that R recruits other proteins which play a role in E2F dis-
placement.
In addition, R binds specifically to the N-terminal region of
Rb, outside the E2F-binding pocket. The deletion of aa 39 to
89, which completely abolished R binding, has been linked to
several functions of Rb. This region was shown to contribute to
growth suppression activity; it was essential for generation of
flat cells in an SAOS2 cell proliferation assay (50). Data sug-
gest that this region may bind the Sp1 inhibitor (9, 39, 72, 73).
Deletion of this region completely abolished the ability of Rb
FIG. 6. Mapping the domains in Rb required for interaction with R protein.
(A) Structures of GST-Rb constructs used for this experiment, which were
generous gifts from Jonathan Horowitz and have been described previously (61).
(B) Lysates from bacterially expressed GST fusion proteins were prepared and
then bound to glutathione beads as described in the text. In vitro-translated
35S-labeled R protein was incubated with beads, GST, or a GSTRb construct as
indicated. After the binding reaction, the complexes were separated by SDS-
PAGE and visualized by autoradiography as described in the text.
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to activate promoters for the human insulin receptor (56) and
insulin-like growth factor II (39) genes through Sp1. This same
region lies within a putative structural domain important for
association of Rb with the p84 nuclear protein and subnuclear
localization of Rb (18). Rb mutant protein deleted in either
region, aa 39 to 89 or aa 249 to 309, was impaired in both
biological activity and the ability to become hyperphosphory-
lated (50). It is possible that R binding specifically affects some
of these functions. Both of these deletions map outside se-
quences that are conserved among the Rb family members.
Therefore, it is unlikely that R will bind p107 or p130, but this
possibility needs to be tested directly. Recently, it has been
shown that the amino terminus of Rb binds and negatively reg-
ulates MCM7, a component of DNA-licensing factor, a com-
plex required for initiation of replication (32). It is possible
that this factor is needed for viral DNA replication and is
displaced from Rb by binding of R.
Two regions in Rb, aa 39 to 89 and aa 249 to 309, may
interact with R, but it is unclear at this point whether either
region is directly bound by R. R may interact with both regions
of Rb, possibly by a primary interaction at one site followed by
contacts at a second site. This type of interaction occurs in
binding of other proteins to Rb (10, 33, 34, 36). The deletion
of aa 39 to 89 is associated with loss of many functions of the
protein and may result in a conformational change in Rb fold-
ing which precludes R binding. Likewise, the decrease in R bind-
ing noted with the deletion of aa 249 to 309 may also be due to
alteration in Rb protein folding which masks the R interaction
domain.
Rb binds within the first 200 aa of the R protein, in the
DNA-binding and dimerization domains. However, neither
dimerization nor DNA binding of R is necessary for its inter-
action with Rb, as the R mutant Rt201, which cannot form
dimers or bind DNA, also binds Rb (44). This finding does not,
however, exclude the possibility that R dimers can bind Rb. It
may be difficult to map this region further by using deletion
mutants of R, as internal deletions within the dimerization
region would severely disrupt protein confirmation. Neither of
the two deletion mutants that we tested, RD2-22 and RD81-
184, bound Rb, and further mapping studies would probably
require point mutations in this region of R.
It is possible that R is a multifunctional protein that plays a
larger role in viral DNA replication than was previously sus-
pected. R, alone or in tandem with Z, can activate viral pro-
moters to regulate viral gene expression during productive
infection. R may also help regulate the cellular environment to
promote viral replication. R can activate c-myc, a cellular gene
important in proliferation (26). R also activates the EBV gene
BHRF1, a viral homolog of the cellular antiapoptotic gene
bcl-2 (28). We show here that R can interact with Rb; there-
fore, R is likely to have a direct effect on cellular proliferation
during the initial stages of viral reactivation.
In addition, R binds to the Rb protein in a region that has
been linked to additional functions of Rb, and this result sug-
gests that interaction of R and Rb may have additional func-
tional consequences beyond relief of Rb-mediated repression
of E2F. R, therefore, may work in tandem with the other major
IE EBV protein, Z, which binds p53, to control cellular envi-
ronment during EBV lytic infection.
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